Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Dose Escalation Study of the CDK4/6 Inhibitor, Palbociclib in Combination With Cetuximab and Intensity Modulated Radiation Therapy (IMRT) for Locally Advanced Unresectable Squamous Cell Carcinoma of the Head and Neck

Next Previous
Trial Profile

A Phase I/II Dose Escalation Study of the CDK4/6 Inhibitor, Palbociclib in Combination With Cetuximab and Intensity Modulated Radiation Therapy (IMRT) for Locally Advanced Unresectable Squamous Cell Carcinoma of the Head and Neck

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Oct 2018

At a glance

  • Drugs Cetuximab (Primary) ; Palbociclib (Primary)
  • Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 03 Sep 2017 Status changed from not yet recruiting to recruiting.
    • 26 Mar 2017 Planned initiation date changed from 1 Feb 2017 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top